Barclays analyst Eliana Merle reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "Our ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'April 28, 2026 2:00 PM TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'April 28, 2026 11:46 AM RBC Capital on BridgeBio Pharma (BBIO): 'we remain buyers'April 28, 2026 11:41 AM William Blair: 'we continue to view BridgeBio as a core smidcap biotech holding'April 28, 2026 11:34 AM Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street'April 28, 2026 11:25 AM Mizuho: 'BBIO could potentially trade in the $90-110+ range today / near-term'April 28, 2026 9:48 AM Barclays: 'We think dropping the question of '441 validity from the case is a major development'April 28, 2026 9:38 AM BridgeBio teams with Morgan Freeman to raise awareness of heart conditionApril 28, 2026 7:31 AM BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. WhiteApril 28, 2026 7:30 AM Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)April 27, 2026 9:29 AM H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)April 27, 2026 6:48 AM